John Carroll

It doesn’t take a lot to dis­rupt a re­la­tion­ship be­tween a bio­phar­ma com­pa­ny and a glob­al CRO/CD­MO. From the small­est start­up shep­herd­ing a sin­gle drug

When CG On­col­o­gy’s $CGON IPO hit a few weeks ago, its suc­cess with in­vestors star­tled a wide swathe of biotech watch­ers who had grown ac­cus­tomed

There may be a sol­id chunk of ex­ec­u­tives in the End­points 100 who feel that bet­ter times are ahead for the biotech in­dus­try in 2024,

Flag­ship Pi­o­neer­ing is stak­ing out a new home base in Asia, re­cruit­ing a long­time McK­in­sey vet — and a col­league to Flag­ship CEO Noubar Afeyan

Weight loss drugs were her­ald­ed as one of the biggest in­no­va­tions in bio­phar­ma in 2023, as the GLP-1 con­tenders swelled in­to megablock­busters. But for one

Feisty, stub­born Jean-Jacques Bi­en­aimé is step­ping down from the top post at Bio­Marin af­ter an 18-year run with a string of high­lights in 2023. And

As the head of John­son & John­son’s on­col­o­gy R&D, Pe­ter Lebowitz’s port­fo­lio ran the sci­en­tif­ic gamut, from dis­cov­ery through de­vel­op­ment and on to the big

The biotech IPO mar­ket crashed hard last year, but we’re see­ing the win­dow creak open in a steady up­ward trend in 2023 that bodes for

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you

Break­through Prop­er­ties is back keep­ing the dirt fly­ing in biotech — this time break­ing new ground in Am­s­ter­dam. The com­mer­cial re­al es­tate al­liance be­tween Tish­man